Report
Martial Descoutures ...
  • Oussema Denguir

Recordati : Des investissements ciblés pour tirer la croissance

>Dynamique de ventes toujours au rendez-vous à fin 2019 - Recordati a publié vendredi dernier ses chiffres préliminaires de l’exercice 2019. La topline progresse de 9.6% à 1.48 Md€ (+0.7% vs Cs), l’EBITDA ressort à 544 M€ (+9% yoy, +0.2% vs Cs) pour un résultat net 11.5% supérieur aux attentes à 369 M€ (+18.1% yoy) bénéficiant d’un one-off d’impôt positif de 27 M€. La croissance demeure principalement tirée par son plus important médicament Zanidip (+11.3%) ainsi que ...
Underlying
Recordati Industria Chimica e Farmaceutica S.p.A.

Recordati-Industria Chimica e Farmaceutica is a pharmaceutical group based in Italy. Co.'s operations are divided into two operating segments: pharmaceuticals (and pharmaceutical chemicals) and orphan drugs. Co.'s products include ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL®, an antihypertensive drug; ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine), an antihypertensive drug discovered and developed in Co.'s research laboratories; UROREC® (silodosin), a new drug indicated for the treatment of benign prostatic hyperplasia; and LIVAZO®/ALIPZA® (pitavastatin), a statin for the treatment of dyslipidemia, among others.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Martial Descoutures

Oussema Denguir

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch